Valuation: ALK-Abelló A/S

Capitalization 56.01B 8.71B 7.5B 6.85B 6.54B 11.99B 836B 12.19B 82.23B 31.82B 397B 32.69B 31.99B 1,382B P/E ratio 2026 *
38.8x
P/E ratio 2027 * 34.1x
Enterprise value 54.29B 8.44B 7.27B 6.64B 6.34B 11.62B 810B 11.81B 79.7B 30.84B 385B 31.68B 31.01B 1,340B EV / Sales 2026 *
7.46x
EV / Sales 2027 * 6.46x
Free-Float
59.15%
Yield 2026 *
0.68%
Yield 2027 * 0.74%
1 day-1.82%
1 week-0.64%
Current month+4.28%
1 month+11.38%
3 months+13.83%
6 months+6.15%
Current year+8.75%
1 week 246.6
Extreme 246.6
255
1 month 208
Extreme 208
262
Current year 192.7
Extreme 192.7
262
1 year 169
Extreme 169
262
3 years 69.9
Extreme 69.9
262
5 years 69.9
Extreme 69.9
262
10 years 32.3
Extreme 32.3
262
Manager TitleAgeSince
Chief Executive Officer 49 31/12/2023
Director of Finance/CFO 54 31/05/2023
Human Resources Officer - 30/09/2019
Director TitleAgeSince
Director/Board Member 57 31/12/2010
Director/Board Member 67 31/12/2013
Director/Board Member 66 11/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
-1.94%-0.64%+45.38%+187.07% 8.71B
-1.77%+2.11%+30.76%+125.49% 896B
+0.12%+2.40%+48.70%+43.08% 546B
-0.46%+3.08%+12.55%+45.72% 372B
-0.46%+2.38%+24.30%+13.90% 328B
+0.74%+3.68%+28.76%+30.24% 283B
+0.53%+1.39%+31.99%+14.29% 282B
-0.07%0.00%+44.09%-2.39% 275B
-4.22%-4.12%-34.43%-51.24% 206B
-0.83%-1.95%+17.16%+44.13% 176B
Average -0.85%+1.88%+24.93%+45.03% 337.21B
Weighted average by Cap. -0.78%+3.16%+27.39%+49.90%

Financials

2026 *2027 *
Net sales 7.28B 1.13B 974M 890M 850M 1.56B 109B 1.58B 10.68B 4.13B 51.54B 4.25B 4.16B 180B 8.26B 1.28B 1.11B 1.01B 964M 1.77B 123B 1.8B 12.12B 4.69B 58.49B 4.82B 4.72B 204B
Net income 1.44B 225M 193M 177M 169M 309M 21.55B 314M 2.12B 820M 10.23B 843M 825M 35.64B 1.64B 255M 219M 201M 191M 351M 24.45B 357M 2.41B 931M 11.61B 956M 936M 40.44B
Net Debt -1.72B -268M -231M -211M -201M -369M -25.73B -375M -2.53B -980M -12.21B -1.01B -985M -42.55B -2.7B -421M -362M -331M -316M -579M -40.36B -589M -3.97B -1.54B -19.16B -1.58B -1.54B -66.75B
Logo ALK-Abelló A/S
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Employees
2,759
Date Price Change Volume
18/05/26 248.40 kr -1.74% 99,968
13/05/26 252.80 kr +0.64% 168,148
12/05/26 251.20 kr +0.40% 198,397
11/05/26 250.20 kr -2.11% 267,830
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
252.80DKK
Average target price
295.00DKK
Spread / Average Target
+16.69%

Quarterly revenue - Rate of surprise